The sterile injectables (SI) market, valued at $586.1 billion in 2024, is projected to exceed $984 billion by 2031 at a 7.7% compound annual growth rate, according to Coherent Market Insights. That growth — driven by biologics, biosimilars and self-administration devices — is pushing pharmaceutical sponsors deeper into reliance on contract manufacturing organizations (CMOs), and making technology transfer between sponsor and contractor sites a make-or-break variable in commercialization timelines.

The analysis, authored by Jim Donovan, MBA, vice president of Pfizer CentreOne, in BioProcess International, frames the transfer problem in concrete operational terms: process variability, scale-up difficulties, and insufficient maintenance of aseptic conditions routinely compromise product quality and regulatory compliance when left unaddressed. The cost is measured in launch delays, not abstractions.

Where transfers fail

Donovan catalogues the failure modes sponsors should audit before signing a transfer agreement:

• misalignment on program expectations, scope, goals and deliverables
• gaps in product knowledge, process understanding and documentation
• lack of standardization at the receiving site, including equipment, process and procedural variations
• insufficient resource and expertise allocation to the transfer itself
• sponsors handing programs to CMOs at different development stages, sometimes forcing further development work and schedule slips
• communication failures rooted in poor transparency between stakeholders
• incompatible data, terminology, standards, systems and protocols

For R&D managers, the budget implication is direct: a program transferred before its process is mature effectively re-enters development at the CMO, with the associated cost and timeline penalties.

Two trends raising the difficulty

The article identifies two structural shifts that amplify these longstanding problems.

Biosimilars. Roughly 45 biosimilars have FDA approval versus 14 reference products, per Samsung Bioepis's 2024 market report. McKinsey projects the global biosimilars market will triple to $74 billion by 2030. In 2020 alone, biosimilars saved the US healthcare system $7.9 billion. But comparability is analytically demanding: sponsors must demonstrate equivalence to reference products across numerous analytical and functional attributes, often requiring bioassays and higher-order protein structure characterization that existing methods cannot deliver unchanged. Process sensitivity compounds the burden — cell culture, purification and formulation variations at a new site can shift critical quality attributes (CQAs) enough to jeopardize the biosimilarity claim. Regional regulatory divergence adds timeline uncertainty that Donovan argues requires flexible documentation and validation protocols.

Device integration. The prefilled syringe market is forecast to grow from $8.7 billion in 2024 to $20.62 billion in 2032 at an 11.4% CAGR (Fortune Business Insights). Autoinjectors, microneedle patches and implantables mean transfers now must cover both drug product and device, pulling formulation scientists, engineers and device manufacturers into a single program. Microneedle patches and implants carry unique manufacturing requirements. Device integration also adds analytical load — sponsors must demonstrate device function and drug release — and draws heightened regulatory scrutiny under standards spanning ISO 13485 and 21 CFR Part 820 alongside drug-approval pathways. That dual compliance burden is a portfolio consideration: partners need documented expertise in both biopharmaceutical and medical-device regulation.

What the author recommends

Donovan prescribes a three-phase transfer structure — scope definition with gap analysis and risk assessment, planning, execution — supported by failure modes and effects analysis (FMEA) to surface risks early. He recommends treating the CMO as an extension of the sponsor's network, with structured onboarding, thorough documentation reviews and proactive identification of critical parameters. Experienced manufacturing staff should close product-knowledge gaps through process mapping and early scale-up risk identification. Dedicated regulatory teams with global reach, he argues, prevent expensive rework.

On execution, the prescription is a "right-first-time" approach: optimized engineering runs, clear batch records, decision trees, and digital infrastructure enabling standardized data protocols and secure sharing.

Caveats for readers

The market figures cited come from commercial market-research firms (Coherent Market Insights, Fortune Business Insights) and consultancies (McKinsey), not from audited data, and the projections to 2030–2032 should be read as forecasts. The author is a vice president at Pfizer CentreOne, a CMO, so the argument that sponsors benefit from partnering with large, experienced contract manufacturers carries an evident commercial interest. The strategies described are process frameworks, not measured outcomes — the piece reports no transfer-specific performance data, such as batch success rates or timeline deltas attributable to FMEA-based planning.

Still, the underlying pressure is real: rising prevalence of cancer, diabetes and autoimmune disorders requiring long-term injectable treatment will keep demand growing, and Donovan's closing argument holds that rigid, one-size-fits-all transfer playbooks cannot absorb evolving biologics regulation and advanced formulation complexity — sponsors that build flexibility into transfer planning are the ones positioned to protect product quality and compress time to market.